Ryvu Therapeutics S.A. (RVU.WA)
PLN 28.4
(4.03%)
PLN 28.4
(4.03%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -92.11 Million PLN | -9.94% |
| 2022 | -83.78 Million PLN | -8.06% |
| 2021 | -77.53 Million PLN | -144.68% |
| 2020 | -31.68 Million PLN | 11.98% |
| 2019 | -35.99 Million PLN | -33758.81% |
| 2018 | -106.32 Thousand PLN | -101.66% |
| 2017 | 6.4 Million PLN | 135.53% |
| 2016 | 2.72 Million PLN | -56.61% |
| 2015 | 6.26 Million PLN | 7.17% |
| 2014 | 5.85 Million PLN | 345.25% |
| 2013 | -2.38 Million PLN | 62.89% |
| 2012 | -6.42 Million PLN | -44.82% |
| 2011 | -4.43 Million PLN | -124.92% |
| 2010 | -1.97 Million PLN | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -19.39 Million PLN | 30.1% |
| 2024 Q2 | -30.41 Million PLN | -56.81% |
| 2023 Q2 | -28.5 Million PLN | -61.48% |
| 2023 Q1 | -17.65 Million PLN | -107.08% |
| 2023 FY | -92.11 Million PLN | -9.94% |
| 2023 Q4 | -27.75 Million PLN | -52.04% |
| 2023 Q3 | -18.25 Million PLN | 35.97% |
| 2022 Q3 | -11.8 Million PLN | 59.67% |
| 2022 Q1 | -26.53 Million PLN | -56.93% |
| 2022 Q2 | -29.26 Million PLN | -10.28% |
| 2022 FY | -83.78 Million PLN | -8.06% |
| 2022 Q4 | -8.52 Million PLN | 27.76% |
| 2021 Q4 | -16.9 Million PLN | 25.89% |
| 2021 Q1 | -13.56 Million PLN | -23.95% |
| 2021 FY | -77.53 Million PLN | -144.68% |
| 2021 Q2 | -24.24 Million PLN | -78.75% |
| 2021 Q3 | -22.81 Million PLN | 5.88% |
| 2020 Q4 | -10.94 Million PLN | 9.84% |
| 2020 FY | -31.68 Million PLN | 11.98% |
| 2020 Q1 | -4.3 Million PLN | 54.61% |
| 2020 Q2 | -4.3 Million PLN | 0.13% |
| 2020 Q3 | -12.13 Million PLN | -182.13% |
| 2019 Q1 | -7.54 Million PLN | 41.65% |
| 2019 Q4 | -9.48 Million PLN | -142.41% |
| 2019 FY | -35.99 Million PLN | -33758.81% |
| 2019 Q3 | -3.91 Million PLN | 56.47% |
| 2019 Q2 | -8.99 Million PLN | -19.13% |
| 2018 Q3 | -3.09 Million PLN | 23.19% |
| 2018 Q4 | -12.93 Million PLN | -317.48% |
| 2018 FY | -106.32 Thousand PLN | -101.66% |
| 2018 Q2 | -4.03 Million PLN | -120.21% |
| 2018 Q1 | 19.96 Million PLN | 889.55% |
| 2017 FY | 6.4 Million PLN | 135.53% |
| 2017 Q3 | 921.07 Thousand PLN | -66.76% |
| 2017 Q1 | 5.24 Million PLN | 46.36% |
| 2017 Q2 | 2.77 Million PLN | -47.16% |
| 2017 Q4 | -2.52 Million PLN | -374.5% |
| 2016 Q1 | -2.33 Million PLN | -272.53% |
| 2016 FY | 2.72 Million PLN | -56.61% |
| 2016 Q4 | 3.58 Million PLN | 37.6% |
| 2016 Q3 | 2.6 Million PLN | 331.01% |
| 2016 Q2 | -1.12 Million PLN | 51.82% |
| 2015 Q4 | 1.35 Million PLN | -14.3% |
| 2015 Q3 | 1.58 Million PLN | -23.04% |
| 2015 Q2 | 2.05 Million PLN | 61.05% |
| 2015 Q1 | 1.27 Million PLN | -40.58% |
| 2015 FY | 6.26 Million PLN | 7.17% |
| 2014 Q1 | 582.06 Thousand PLN | 79.93% |
| 2014 Q4 | 2.14 Million PLN | 31.76% |
| 2014 Q3 | 1.63 Million PLN | 8.39% |
| 2014 Q2 | 1.5 Million PLN | 158.39% |
| 2014 FY | 5.85 Million PLN | 345.25% |
| 2013 Q4 | 323.49 Thousand PLN | 142.78% |
| 2013 FY | -2.38 Million PLN | 62.89% |
| 2013 Q1 | -995.97 Thousand PLN | 50.01% |
| 2013 Q2 | -956.77 Thousand PLN | 3.94% |
| 2013 Q3 | -756.09 Thousand PLN | 20.98% |
| 2012 Q3 | -939.84 Thousand PLN | 48.85% |
| 2012 FY | -6.42 Million PLN | -44.82% |
| 2012 Q2 | -1.83 Million PLN | -10.77% |
| 2012 Q1 | -1.65 Million PLN | 0.0% |
| 2012 Q4 | -1.99 Million PLN | -112.0% |
| 2011 FY | -4.43 Million PLN | -124.92% |
| 2010 FY | -1.97 Million PLN | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bioceltix S.A. | -13.68 Million PLN | -572.962% |
| BIOTON S.A. | 2.27 Million PLN | 4148.879% |
| Captor Therapeutics Spolka Akcyjna | -70.58 Million PLN | -30.5% |
| Mabion S.A. | 41.26 Million PLN | 323.199% |
| Molecure S.A. | -18.3 Million PLN | -403.119% |
| NanoGroup S.A. | -7.88 Million PLN | -1067.479% |
| Pharmena S.A. | 28.94 Million PLN | 418.275% |
| Poltreg S.A. | -13.55 Million PLN | -579.743% |
| Pure Biologics Spólka Akcyjna | -35.69 Million PLN | -158.06% |
| Synthaverse S.A. | 4.75 Million PLN | 2035.939% |
| Urteste S.A. | -5.58 Million PLN | -1548.98% |